Author

Henrik Albæk Jacobsen

THE REAL-WORLD EFFICACY AND SAFETY OF VEDOLIZUMAB IN BIO-NAïVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE - AN INTERIM ANALYSIS FROM A DANISH NATIONAL COHORT STUDY
THE REAL-WORLD EFFICACY AND SAFETY OF VEDOLIZUMAB IN BIO-NAïVE PATIENTS WITH INFLAMMATORY BOWEL DISEASE - AN INTERIM ANALYSIS FROM A DANISH NATIONAL COHORT STUDY

Henrik Albæk Jacobsen  et al.

VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES
VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY IN ELDERLY PATIENTS AND THOSE WITH CONTRAINDICATIONS FOR ANTI-TNF THERAPY: A REAL-WORLD, NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Henrik Albæk Jacobsen  et al.

Item 1 - 2 / 2
1